NFKB1 and head and neck squamous cell carcinoma: Our previous pre-clinical and clinical studies with a first-generation proteasome inhibitor, Bortezomib, demonstrated inhibition of NFκB activity and anti-tumor activity in HNSCC, but these responses were transient and sustained treatment was limited by toxicity [34, 35].